JP2010527981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010527981A5 JP2010527981A5 JP2010508909A JP2010508909A JP2010527981A5 JP 2010527981 A5 JP2010527981 A5 JP 2010527981A5 JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010527981 A5 JP2010527981 A5 JP 2010527981A5
- Authority
- JP
- Japan
- Prior art keywords
- week
- chk
- administered
- treatment
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94020307P | 2007-05-25 | 2007-05-25 | |
| PCT/GB2008/050372 WO2008146035A1 (en) | 2007-05-25 | 2008-05-23 | Combination of chk and parp inhibitors for the treatment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010527981A JP2010527981A (ja) | 2010-08-19 |
| JP2010527981A5 true JP2010527981A5 (enExample) | 2011-06-30 |
Family
ID=39672970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010508909A Pending JP2010527981A (ja) | 2007-05-25 | 2008-05-23 | 癌処置用のｃｈｋ阻害剤およびｐａｒｐ阻害剤の組み合わせ剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100249112A1 (enExample) |
| EP (1) | EP2167086A1 (enExample) |
| JP (1) | JP2010527981A (enExample) |
| KR (1) | KR20100020981A (enExample) |
| CN (1) | CN101743003A (enExample) |
| AU (1) | AU2008256562A1 (enExample) |
| BR (1) | BRPI0811059A2 (enExample) |
| CA (1) | CA2687786A1 (enExample) |
| MX (1) | MX2009012705A (enExample) |
| RU (1) | RU2009147819A (enExample) |
| WO (1) | WO2008146035A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010081778A1 (en) * | 2009-01-17 | 2010-07-22 | Universität Zürich | Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer |
| US8871765B2 (en) | 2010-07-27 | 2014-10-28 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors |
| ES2654670T3 (es) | 2012-04-05 | 2018-02-14 | Vertex Pharmaceuticals Incorporated | Compuestos útiles como inhibidores de la cinasa ATR y terapias de combinación de los mismos |
| SG11201503670YA (en) | 2012-12-31 | 2015-07-30 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3609884A4 (en) * | 2017-04-10 | 2021-01-06 | Sierra Oncology, Inc. | CHK1 (SRA737) / PAPI COMBINATION METHOD FOR INHIBITION OF TUMOR GROWTH |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| WO2019194738A1 (en) | 2018-04-05 | 2019-10-10 | Noviga Research Ab | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022000946A1 (zh) * | 2020-06-29 | 2022-01-06 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| CN112375070B (zh) * | 2020-06-29 | 2023-03-28 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05009661A (es) * | 2003-03-12 | 2006-03-08 | Kudos Pharm Ltd | Derivados de ftalazinona. |
| CA2547077C (en) * | 2003-12-01 | 2015-11-03 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
| DE602004031777D1 (en) * | 2004-01-05 | 2011-04-21 | Astrazeneca Ab | Thiophenderivate als chk-1-inhibitoren |
| EP1836320A2 (en) * | 2005-01-07 | 2007-09-26 | Arqule, Inc. | Compositions for modulation of parp and methods for screening for same |
| WO2008020180A2 (en) * | 2006-08-17 | 2008-02-21 | Kudos Pharmaceuticals Limited | Methods of increasing the sensitivity of cancer cells to dna damage |
-
2008
- 2008-05-23 RU RU2009147819/15A patent/RU2009147819A/ru not_active Application Discontinuation
- 2008-05-23 US US12/601,328 patent/US20100249112A1/en not_active Abandoned
- 2008-05-23 EP EP08750767A patent/EP2167086A1/en not_active Withdrawn
- 2008-05-23 CA CA2687786A patent/CA2687786A1/en not_active Abandoned
- 2008-05-23 CN CN200880024432A patent/CN101743003A/zh active Pending
- 2008-05-23 AU AU2008256562A patent/AU2008256562A1/en not_active Abandoned
- 2008-05-23 WO PCT/GB2008/050372 patent/WO2008146035A1/en not_active Ceased
- 2008-05-23 KR KR1020097026995A patent/KR20100020981A/ko not_active Withdrawn
- 2008-05-23 BR BRPI0811059A patent/BRPI0811059A2/pt not_active IP Right Cessation
- 2008-05-23 MX MX2009012705A patent/MX2009012705A/es unknown
- 2008-05-23 JP JP2010508909A patent/JP2010527981A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010527981A5 (enExample) | ||
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| JP2024133474A5 (enExample) | ||
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
| FI2694072T4 (fi) | Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa | |
| JP2014515373A5 (enExample) | ||
| EP2512479A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| NZ606825A (en) | Methods and compositions for treating complement-associated disorders | |
| JP2014528901A5 (enExample) | ||
| NZ714963A (en) | Compositions and methods for treating anemia | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| JP2016529285A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2016516773A5 (enExample) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| UA104148C2 (ru) | [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1h-индол-3-ил]-метанон как ингибитор триптазы тучных клеток | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| JP2013544892A5 (enExample) | ||
| IL259512B2 (en) | Combination for the effective treatment of metastatic cancer in patients | |
| JP2008534503A5 (enExample) | ||
| JP2019065009A5 (enExample) |